KRAS
Entity.
- Evidence
- 415 documents · 168 separate publishers
- Standing
- A name from our starting list; its record is kept up to date automatically from coverage
- Time
- first seen 11 Mar 2026, last seen 7 Oct 2026
- Measured
- 13% of mentions say something specific about it; the rest only name it
- As of
- 8 Oct 2026
Where this comes from
- J Thromb Haemost · 2026-10-03 · KRAS Mutation and Venous Thromboembolism Risk in Colorectal Cancer: A Danish Population-Based Cohort Study. (opens the source in a new tab)
- Int J Cancer · 2026-10-02 · Spatial Transcriptomic Profiling Reveals a Fibroblast-Associated Extracellular Matrix Niche in KRAS G12C-Mutant Lung Adenocarcinoma Primary Tumors From Patients With Metas… (opens the source in a new tab)
- Fierce Pharma · 2026-10-02 · Fierce Pharma Asia—AZ’s $2B bet on ivonescimab; Novo buys Hengrui GLP-1; Merck doubles down on KRAS (opens the source in a new tab)
- bioRxiv Cancer Biology · 2026-10-02 · Acute Metabolic Switch by High-Dose Dehydroascorbic Acid: Rapid TCA Cycle Depletion and Early Signature of Methionine Trap within 1 Hour in KRAS-Mutant Cells (opens the source in a new tab)
- Future Oncol · 2026-10-01 · SUNRAY-02: a study of olomorasib combined with immunotherapy in stage II-III KRAS G12C-mutant non-small cell lung cancer after definitive therapy. (opens the source in a new tab)
- GEN · 2026-09-30 · Merck, SciBrunch Launch Up-to-$2.13B Collaboration to Develop Preclinical KRAS-Inhibiting Molecular Glue (opens the source in a new tab)
- Sci Transl Med · 2026-09-30 · FAK inhibitor and RAF/MEK clamp avutometinib enhance KRAS G12C inhibitor efficacy in preclinical models of non-small cell lung cancer. (opens the source in a new tab)
- Endpoints News · 2026-09-29 · Merck licenses a KRAS G12D inhibitor for $400M upfront (opens the source in a new tab)
- Fierce Biotech · 2026-09-28 · Merck pens $2.1B deal with China’s SciBrunch to chase KRAS G12D (opens the source in a new tab)